Results are expected in the first quarter of 2021. We expect data from this study in the first quarter of 2022. Any of these companies may develop competing products more rapidly than we do. The claims are directed to the T-COVID therapeutic composition and its method of use. NasoShield is further covered by an issued and pending U.S. patent. Compliance with these laws is difficult, constantly evolving, and time consuming. CMS publishes information from these reports on a publicly available website. This has led to significant variations in the regimes of the different member states. EMA guidance details the procedures for requesting scientific advice. Nonetheless, some biologics are still approved at the member state level. MAAs for biologics also must meet special requirements. As of December 31, 2020, we have an accumulated deficit of $186.4 million. We do not know whether or when we will generate product revenues or become profitable. We have not completed pivotal clinical trials for any product candidate. In addition, other unanticipated costs may arise. This, in turn, would significantly adversely affect our business prospects. Our acquisitions may expose us to unknown liabilities. Additionally, product approvals may be delayed as a result of the COVID-19 pandemic. Litigation may be necessary to defend against these claims. Such a license may not be available on commercially reasonable terms or at all. In addition, the GDPR includes restrictions on cross-border data transfers. Manufacturers are excluded from this protection in cases of willful misconduct.